Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amcenestrant plus palbociclib versus letrozole plus palbociclib in first-line ER-positive/HER2-negative advanced breast cancer
jRCT2031200210Phase 3Completed
- Sponsor
- Sanofi
- Start
- Dec 2020
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of amcenestrant in breast cancer (2 arms), sponsored by Sanofi. Primary endpoint: Progression-free survival. Started Dec 2020; status: completed.
02
Drugs
amcenestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2031200210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200210.